Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors.

Apostolia-Maria TsimberidouClaire F VerschraegenRobert WesolowskiChi-Sheng ShiaPei HsuTillman E Pearce

Published in: British journal of cancer (2023)

once every 3 weeks. OBI-3424 was well tolerated; dose-dependent, noncumulative thrombocytopenia and anemia were dose-limiting.

Keyphrases